JPMorgan Chase & Co. Cuts Ardent Health (NYSE:ARDT) Price Target to $11.00

Ardent Health (NYSE:ARDT) had its target price lowered by JPMorgan Chase & Co. from $12.00 to $11.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group assumed coverage on Ardent Health in a research note on Tuesday, October 14th. They set a “neutral” rating and a $19.00 price target on the stock. Mizuho dropped their price objective on Ardent Health from $20.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Truist Financial cut their target price on shares of Ardent Health from $21.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. KeyCorp cut shares of Ardent Health from an “overweight” rating to a “sector weight” rating in a research report on Monday, November 17th. Finally, Stephens dropped their price target on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Friday, November 14th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $14.58.

Ardent Health Trading Up 1.1%

Shares of NYSE ARDT opened at $8.64 on Tuesday. Ardent Health has a 1-year low of $8.22 and a 1-year high of $15.65. The company has a 50-day moving average of $8.83 and a two-hundred day moving average of $11.61. The company has a market cap of $1.24 billion, a PE ratio of 5.96, a P/E/G ratio of 4.95 and a beta of 0.72. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.55 billion. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. As a group, equities analysts expect that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Oliver Luxxe Assets LLC grew its holdings in Ardent Health by 1.5% during the second quarter. Oliver Luxxe Assets LLC now owns 87,639 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,319 shares during the period. Geode Capital Management LLC boosted its position in shares of Ardent Health by 0.6% during the second quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock worth $3,918,000 after purchasing an additional 1,769 shares in the last quarter. CWM LLC boosted its position in shares of Ardent Health by 990.6% during the second quarter. CWM LLC now owns 2,203 shares of the company’s stock worth $30,000 after purchasing an additional 2,001 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Ardent Health by 8.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,530 shares of the company’s stock valued at $376,000 after buying an additional 2,110 shares during the period. Finally, Strs Ohio increased its position in shares of Ardent Health by 6.3% in the 3rd quarter. Strs Ohio now owns 42,400 shares of the company’s stock valued at $562,000 after buying an additional 2,500 shares in the last quarter.

Ardent Health News Roundup

Here are the key news stories impacting Ardent Health this week:

• Neutral Sentiment: One outlet published a “bull case” overview of ARDT, which may be of interest to contrarian investors but does not offset the near‑term legal/analyst headwinds. Ardent Health, Inc. (ARDT): A Bull Case Theory
• Negative Sentiment: Hagens Berman is notifying investors that a securities class action has been filed alleging Ardent misled investors about revenue recognition systems and the adequacy of professional‑liability reserves following poor Q3 results—this raises the risk of damages, defense costs and potential reserve increases. Ardent Health (ARDT) Hit With Securities Class Action Over Alleged Accounting Deception – Hagens Berman
• Negative Sentiment: Bleichmar Fonti & Auld (BFA) says it has filed a class action after a roughly 33% stock decline; filing firms typically seek lead plaintiffs and damages—such litigation can pressure sentiment and raise potential payout/settlement risk. ARDT STOCK DROP: BFA Law Hits Ardent Health Inc with Securities Class Action
• Negative Sentiment: Numerous national plaintiff firms (Levi & Korsinsky, Rosen, Pomerantz, Faruqi, Robbins Geller, Kahn Swick & Foti, Glancy, Robbins Geller, etc.) have issued notices urging investors to seek lead‑plaintiff status before the March 9, 2026 deadline—the proliferation of solicitations underscores broad litigation risk and market uncertainty. Levi & Korsinsky Reminder
• Negative Sentiment: Kuehn Law and other filings highlight specific allegations about Ardent’s accounts‑receivable practices (a “180‑day cliff” reserve approach) and alleged misstatements about collection‑review processes and malpractice insurance—if proven, these could force restatements or higher reserves. Kuehn Law Encourages Investors
• Negative Sentiment: Analyst coverage has turned more bearish—reports indicate JPMorgan lowered its expectations and an analyst downgrade pushed ARDT to a new 1‑year low, which can amplify selling pressure and lower short‑term price targets. JPMorgan Lowers Expectations / Analyst Downgrade

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.